Baicalein / Hif1a Cancer Research Results

Ba, Baicalein: Click to Expand ⟱

Features:

Baicalein — Baicalein is a polyphenolic flavone aglycone found primarily in Scutellaria baicalensis and related botanicals, and is the active unconjugated counterpart of baicalin after intestinal/microbial deconjugation and re-conjugation cycling. It is formally classified as a small-molecule natural-product flavonoid with pleiotropic signaling, redox, metabolic, and enzyme-modulatory activity. Standard abbreviations include Ba or BE. In cancer literature it is best characterized as a multi-target preclinical anticancer scaffold rather than an established oncology drug, with relatively strong mechanistic support for apoptosis induction, survival-pathway suppression, anti-invasive signaling, and 12-lipoxygenase inhibition, but with major translational constraints from poor aqueous solubility, extensive first-pass glucuronidation/sulfation, transporter-enzyme interactions, and the likelihood that many in-vitro exposure levels exceed typical systemic aglycone exposure.

Primary mechanisms (ranked):

12-lipoxygenase inhibition with downstream suppression of pro-survival, pro-migratory, and pro-angiogenic lipid signaling.
Intrinsic apoptosis induction via mitochondrial destabilization, cytochrome-c release, caspase-9/3 activation, and BAX:BCL-2 shift.
PI3K/AKT survival-axis repression, often with PTEN restoration and reduced downstream anti-apoptotic signaling.
Redox stress modulation with tumor-context ROS↑ and impaired antioxidant buffering, but normal-cell antioxidant protection in oxidative-injury models.
ER-stress and Ca²⁺ stress coupling that amplifies mitochondrial commitment to cell death.
Suppression of glycolysis / hypoxia adaptation, including HIF-1α, HK2, LDHA, PDK1, PKM2, and GLUT1 in relevant models.
Anti-invasive / anti-metastatic signaling through MMP2/MMP9 and related migration programs.
Anti-angiogenic signaling with VEGF reduction.
Contextual chemo- and radiosensitization in selected models.

Bioavailability / PK relevance: Oral translation is constrained by very low water solubility and extensive intestinal/hepatic phase-II metabolism to glucuronide and sulfate conjugates. Human phase-I data show rapid absorption of tablet formulations with peak plasma levels around 2 hours, steady state after repeated dosing, and major circulating/excreted metabolite burden rather than sustained high parent-aglycone exposure. Microbiota, UGT-dependent reconjugation, and transporter/CYP interactions are clinically relevant variables. Intestinal microbiota are mechanistically relevant because baicalin is converted to baicalein before absorption. Poor translational PK is reinforced by very low aqueous solubility, reported around 16.82 μg/mL, and by formulation studies showing large exposure gains after cocrystal/nanodelivery approaches.

In-vitro vs systemic exposure relevance: Many anticancer cell studies use roughly 10–50 μM and sometimes higher. That generally exceeds typical reported average human plasma exposure for parent baicalein after oral dosing, so direct translation of higher-concentration in-vitro effects should be treated cautiously unless formulation enhancement, local delivery, tissue enrichment, conjugate deconjugation, or combination use is specifically justified.

Clinical evidence status: Strong preclinical evidence across multiple tumor models; limited animal efficacy support; human clinical experience is mainly phase-I safety/PK and non-oncology development contexts. There is no established cancer indication or mainstream regulatory oncology deployment as of March 12, 2026.

Here are some of the key pathways and mechanisms implicated in its anticancer effects:
-Apoptosis and Cell Cycle Regulation
-Reactive Oxygen Species ROS↑ Generation and Oxidative Stress (Context and dose dependent)
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, Ca+2↑, Cyt‑c↑, Caspase-3↑, Caspase-9↑, DNA damage↑,
-Baicalein’s effects on ROS are context-dependent. In some cancer cells, it promotes ROS production to a degree that overwhelms the antioxidant defenses. Elevated ROS levels can damage cellular components and promote apoptosis, essentially tipping the balance toward cell death.
-Conversely, in normal cells, baicalein may exhibit antioxidant properties and reduce ROS↓ under conditions of oxidative stress, highlighting its dual role.
- May Lowers AntiOxidant defense in Cancer Cells: NRF2↓, GSH↓, HO-1↓
- Raises AntiOxidant defense in Normal Cells: NRF2↑, SOD↑, GSH↑, Catalase↑, HO-1↑,
-MAPK, ERK Pathway:
-PI3K/Akt Pathway: Inhibition of the PI3K, Akt pathway by baicalein.
-NF-κB Pathway: Baicalein can inhibit
-Inhibition of Metastasis and Invasion: Baicalein can downregulate MMPs, MMP2, MMP9
-Angiogenesis Suppression: VEGF
-Baicalein is a well-known inhibitor of 12-lipoxygenase
-inhibitor of Glycolysis↓ and Hif1a">HIF-1α↓, PKM2↓, cMyc↓, PDK1↓, GLUT1↓, LDHA↓, HK2↓
- promoting PTEN
-chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, neuroprotective, Cognitive, Renoprotection, Hepatoprotective, cardioProtective,
- Selectivity: Cancer Cells vs Normal Cells
-low bioavailability but liposomal may improve bioavailability

In summary, baicalein affects cancer cells by modulating multiple pathways—promoting apoptosis, causing cell cycle arrest, generating or modulating ROS levels, inhibiting survival and proliferative signaling (such as MAPK, PI3K/Akt, and NF-κB pathways), and reducing angiogenesis and metastasis.

Many animal studies, doses have been reported in the range of approximately 10 to 200 mg/kg body weight.
For example, some studies exploring anticancer or anti-inflammatory effects in rodent models have used doses around 50–100 mg/kg.
However, these doses do not directly translate to human dosages.
Some human studies or formulations (where they are used as nutraceuticals or supplements) may suggest dosing in the range of a few hundred milligrams per day of the extract, but it is often not standardized to a specific amount of baicalein or baicalin.
-mix with oil?

-ic50 cancer cells 10-30uM, normal cells 50-100uM
-Animal studies, 10 to 100 mg/kg.
-Reported to induce apoptosis, cause cell cycle arrest, inhibit angiogenesis, and modulate various signaling pathways (e.g., STAT3, NF-κB, MAPK).

Mechanistic table

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	12-Lipoxygenase axis	↓ 12-LOX, ↓ 12-HETE-linked survival / migration signaling	↔ or modest effect	P, R	Direct target-level antitumor leverage	One of the more mechanistically specific baicalein actions. Supports anti-proliferative, anti-migratory, and anti-angiogenic behavior in susceptible tumors.
2	Mitochondria / MPTP	↓ ΔΨm, ↑ mitochondrial dysfunction, ↑ Cyt-c release	↔ or protected in oxidative-injury models	R, G	Intrinsic apoptosis commitment	Mitochondrial collapse is a major convergence point downstream of redox, ER-stress, and survival-pathway suppression.
3	Caspase apoptosis program	↑ BAX, ↓ Bcl-2, ↑ Casp9, ↑ Casp3, ↑ apoptosis	↔ minimal activation	G	Cell-death execution	Widely reported across tumor models; often follows mitochondrial injury rather than representing the earliest event.
4	PI3K / AKT / PTEN axis	↓ PI3K, ↓ p-AKT, ↑ PTEN	↔ or context-dependent	R, G	Survival suppression	A central non-redox pathway that helps explain apoptosis sensitization, cell-cycle arrest, and metabolic downshift.
5	ROS balance	↑ ROS (dose-dependent) or ROS⇅ depending on model	↓ ROS under oxidative challenge	P, R, G	Tumor-selective redox stress	Dual behavior is important: pro-oxidant pressure is common in malignant cells, whereas antioxidant cytoprotection is well documented in stressed non-malignant cells.
6	NRF2 / HO-1 / GSH antioxidant buffering	↓ NRF2, ↓ HO-1, ↓ GSH (context-dependent)	↑ NRF2, ↑ HO-1, ↑ GSH, ↑ SOD / catalase	R, G	Selectivity gate	This divergent redox-buffer response likely contributes to cancer-versus-normal selectivity, but it is model-dependent and should not be overstated as universal.
7	ER stress and Ca²⁺ stress coupling	↑ ER stress, ↑ CHOP, ↑ UPR, ↑ Ca²⁺ dysregulation	↔ buffered homeostasis	R, G	Stress amplification	Likely helps transmit redox/survival perturbation into irreversible mitochondrial death signaling.
8	Glycolysis / HIF-1α adaptation	↓ HIF-1α, ↓ HK2, ↓ LDHA, ↓ PDK1, ↓ PKM2, ↓ GLUT1, ↓ glycolysis	↔	G	Metabolic constraint	Most convincing in hypoxia-adaptation and gastric / radioresistance models. Usually reflects later transcriptional or adaptation-level effects.
9	NF-κB and MAPK / ERK signaling	↓ NF-κB, MAPK / ERK modulation (often ↓ ERK tone)	↔ or context-dependent	P, R, G	Signal reprogramming	Supports lower inflammatory-survival tone, apoptosis sensitization, and reduced proliferation, but exact direction within MAPK branches can vary by tumor model.
10	Invasion / metastasis axis	↓ MMP2, ↓ MMP9, ↓ migration / invasion	↔	G	Anti-invasive phenotype	Phenotypically important and relatively consistent, though usually secondary to broader signaling reprogramming.
11	Angiogenesis axis	↓ VEGF, ↓ microvessel support	↔	G	Anti-angiogenic support	Supported by xenograft and lung-cancer data; best viewed as an adjunct downstream effect rather than sole primary mechanism.
12	Radiosensitization / chemosensitization	↑ treatment sensitivity (context-dependent)	Potential normal-tissue protection in oxidative-injury contexts	G	Combination-use leverage	Mechanistically plausible via HIF-1α/glycolysis suppression, NF-κB restraint, and apoptosis priming, but still preclinical and heterogeneous.
13	Clinical Translation Constraint	Low parent exposure, variable microbiota handling, rapid conjugation, likely concentration gap	May favor safety but complicates efficacy extrapolation	G	Delivery limitation	Poor solubility, strong first-pass metabolism, conjugate predominance, possible CYP/transporter interactions, and lack of oncology-grade clinical validation are the main barriers.

Time-Scale Flag (TSF): P / R / G

P: 0–30 min (primary/physical–chemical effects; direct enzymatic or rapid signaling shifts)
R: 30 min–3 hr (redox signaling and acute stress-response signaling)
G: >3 hr (gene-regulatory adaptation and phenotype-level outcomes)

Hif1a, HIF1α/HIF1a: Click to Expand ⟱

Source:

Type:

Hypoxia-Inducible-Factor 1A (HIF1A gene, HIF1α, HIF-1α protein product)
-Dominantly expressed under hypoxia(low oxygen levels) in solid tumor cells
-HIF1A induces the expression of vascular endothelial growth factor (VEGF)
-High HIF-1α expression is associated with Poor prognosis
-Low HIF-1α expression is associated with Better prognosis

-Functionally, HIF-1α is reported to regulate glycolysis, whilst HIF-2α regulates genes associated with lipoprotein metabolism.
-Cancer cells produce HIF in response to hypoxia in order to generate more VEGF that promote angiogenesis

Key mediators of aerobic glycolysis regulated by HIF-1α.
-GLUT-1 → regulation of the flux of glucose into cells.
-HK2 → catalysis of the first step of glucose metabolism.
-PKM2 → regulation of rate-limiting step of glycolysis.
-Phosphorylation of PDH complex by PDK → blockage of OXPHOS and promotion of aerobic glycolysis.
-LDH (LDHA): Rapid ATP production, conversion of pyruvate to lactate;

HIF-1α Inhibitors:
-Curcumin: disruption of signaling pathways that stabilize HIF-1α (ie downregulate).
-Resveratrol: downregulate HIF-1α protein accumulation under hypoxic conditions.
-EGCG: modulation of upstream signaling pathways, leading to decreased HIF-1α activity.
-Emodin: reduce HIF-1α expression. (under hypoxia).
-Apigenin: inhibit HIF-1α accumulation.

Scientific Papers found: Click to Expand⟱

2626-

Ba,

Molecular targets and therapeutic potential of baicalein: a review

Review,

Var,

Review,

AD,

Review,

Stroke,

AntiCan↓, *neuroP↑, *cardioP↑, *hepatoP↑, *RenoP↑, TumCCA↑, CDK4↓, cycD1/CCND1↓, cycE/CCNE↑, BAX↑, Bcl-2↓, VEGF↓, Hif1a↓, cMyc↓, NF-kB↓, ROS↑, BNIP3↑, *neuroP↑, *cognitive↑, *NO↓, *iNOS↓, *COX2↓, *PGE2↓, *NRF2↑, *p‑AMPK↑, *Ferroptosis↓, *lipid-P↓, *ALAT↓, *AST↓, *Fas↓, *BAX↓, *Apoptosis↓,

2620-

Ba,

Natural compounds targeting glycolysis as promising therapeutics for gastric cancer: A review

Review,

GC,

Hif1a↓, HK2↓, LDHA↓, PDK1↓, p‑Akt↓, PTEN↑, GlucoseCon↓, lactateProd↓, Glycolysis↓,

2617-

Ba,

Potential of baicalein in the prevention and treatment of cancer: A scientometric analyses based review

Review,

Var,

Ca+2↑, MMP2↓, MMP9↓, Vim↓, Snail↓, E-cadherin↑, Wnt↓, β-catenin/ZEB1↓, p‑Akt↓, p‑mTOR↓, NF-kB↓, i-ROS↑, Bcl-2↓, BAX↑, Cyt‑c↑, Casp3↑, Casp9↑, STAT3↓, IL6↓, MMP2↓, MMP9↓, NOTCH↓, PPARγ↓, p‑NRF2↓, HK2↓, LDHA↓, PDK1↓, Glycolysis↓, PTEN↑, Akt↓, Hif1a↓, MMP↓, VEGF↓, VEGFR2↓, TOP2↓, uPA↓, TIMP1↓, TIMP2↓, cMyc↓, TrxR↓, ASK1↑, Vim↓, ZO-1↑, E-cadherin↑, SOX2↓, OCT4↓, Shh↓, Smo↓, Gli1↓, N-cadherin↓, XIAP↓,

2615-

Ba,

The Multifaceted Role of Baicalein in Cancer Management through Modulation of Cell Signalling Pathways

Review,

Var,

*AntiCan↓, *Inflam↓, TumCP↓, NF-kB↓, PPARγ↑, TumCCA↑, JAK2↓, STAT3↓, TumCMig↓, Glycolysis↓, MMP2↓, MMP9↓, selectivity↑, VEGF↓, Hif1a↓, cMyc↓, ChemoSen↑, ROS↑, p‑mTOR↓, PTEN↑,

2289-

Ba,

Rad,

Baicalein Inhibits the Progression and Promotes Radiosensitivity of Esophageal Squamous Cell Carcinoma by Targeting HIF-1A

in-vitro,

ESCC,

KYSE150

20uM

TumCP↓, TumCMig↓, Glycolysis↓, cycD1/CCND1↓, CDK4↓, ECAR↓, TumCCA↑, HK1↓, ALDH↓, ALDOA↓, PKM2↓, Hif1a↓,

2290-

Ba,

Research Progress of Scutellaria baicalensis in the Treatment of Gastrointestinal Cancer

Review,

GI,

p‑mTOR↓, p‑Akt↓, p‑IKKα↓, NF-kB↓, PI3K↓, Akt↓, ROCK1↓, GSK‐3β↓, CycB/CCNB1↓, cycD1/CCND1↓, cycA1/CCNA1↑, CDK4↓, P53↑, P21↑, TumCCA↑, MMP2↓, MMP9↓, EMT↓, Hif1a↓, Shh↓, PD-L1↓, STAT3↓, IL1β↓, IL2↓, IL6↓, PKM2↓, HDAC10↓, P-gp↓, Bcl-xL↓, eff↓, BioAv↓, BioAv↑,

996-

Ba,

Tam,

Baicalein resensitizes tamoxifen‐resistant breast cancer cells by reducing aerobic glycolysis and reversing mitochondrial dysfunction via inhibition of hypoxia‐inducible factor‐1α

Hif1a↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, lact/pyru↓, ROS↑, Apoptosis↑,

2291-

Ba,

BA,

Baicalein and Baicalin Promote Melanoma Apoptosis and Senescence via Metabolic Inhibition

in-vitro,

Melanoma,

SK-MEL-28

0-40uM

in-vitro,

Melanoma,

A375

LDHA↓, ENO1↓, PKM2↓, GLUT1↓, GLUT3↓, HK2↓, PFK1↓, GPI↓, TPI↓, GlucoseCon↓, TumCG↓, TumCP↓, mTORC1↓, Hif1a↓, Ki-67↓,

2474-

Ba,

Anticancer properties of baicalein: a review

Review,

Var,

in-vitro,

Nor,

BV2

ROS⇅, ROS↑, ER Stress↑, Ca+2↑, Apoptosis↑, eff↑, DR5↑, 12LOX↓, Cyt‑c↑, Casp7↑, Casp9↑, Casp3↑, cl‑PARP↑, TumCCA↑, cycE/CCNE↑, CDK4↓, cycD1/CCND1↓, VEGF↓, cMyc↓, Hif1a↓, NF-kB↓, BioEnh↑, BioEnh↑, P450↓, *Hif1a↓, *iNOS↓, *COX2↓, *VEGF↓, *ROS↓, *PI3K↓, *Akt↓,

2391-

Ba,

Scutellaria baicalensis and its flavonoids in the treatment of digestive system tumors

Review,

GC,

Hif1a↓, PKM2↓, RadioS↑, Glycolysis↓, PAK↓,

2298-

Ba,

Flavonoids Targeting HIF-1: Implications on Cancer Metabolism

Review,

Var,

TumCG↓, TumCP↓, Hif1a↓, VEGF↓, ChemoSen↑, Glycolysis↓, HK2↓, PDK1↓, LDHA↓, p‑Akt↓, PTEN↑,

2297-

Ba,

Significance of flavonoids targeting PI3K/Akt/HIF-1α signaling pathway in therapy-resistant cancer cells – A potential contribution to the predictive, preventive, and personalized medicine

Review,

Var,

Glycolysis↓, Hif1a↓, PKM2↓, RadioS↑,

2295-

Ba,

5-FU,

Baicalein reverses hypoxia-induced 5-FU resistance in gastric cancer AGS cells through suppression of glycolysis and the PTEN/Akt/HIF-1α signaling pathway

in-vitro,

GC,

AGS

ChemoSen↑, HK2↓, LDHA↓, PDK1↓, Akt↓, PTEN↑, Hif1a↓, Glycolysis↓, ROS↑, CHOP↑,

2293-

Ba,

Baicalein suppresses inflammation and attenuates acute lung injury by inhibiting glycolysis via HIF‑1α signaling

in-vitro,

Nor,

MH-S

40, 20 and 10 µM

present study aimed to investigate the effects of baicalein on lung injury and inflammation

in-vivo,

NA,

30 male C57BL/6 mice

*Hif1a↓, *Glycolysis↓, *Inflam↓, *HK2↓, *PFK1↓, *PKM2↓,

Showing Research Papers: 1 to 14 of 14

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 14

Pathway results for Effect on Cancer / Diseased Cells:

Functional Outcomes ⓘ

AntiCan↓, 1,
Total Targets: 111

Pathway results for Effect on Normal Cells:

Redox & Oxidative Stress ⓘ

Ferroptosis↓, 1, lipid-P↓, 1, NRF2↑, 1, ROS↓, 1,

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1, p‑AMPK↑, 1, Glycolysis↓, 1, HK2↓, 1, PFK1↓, 1, PKM2↓, 1,

Cell Death ⓘ

Akt↓, 1, Apoptosis↓, 1, BAX↓, 1, Fas↓, 1, Ferroptosis↓, 1, iNOS↓, 2,

Proliferation, Differentiation & Cell State ⓘ

PI3K↓, 1,

Angiogenesis & Vasculature ⓘ

Hif1a↓, 2, NO↓, 1, VEGF↓, 1,

Immune & Inflammatory Signaling ⓘ

COX2↓, 2, Inflam↓, 2, PGE2↓, 1,

Clinical Biomarkers ⓘ

ALAT↓, 1, AST↓, 1,

Functional Outcomes ⓘ

AntiCan↓, 1, cardioP↑, 1, cognitive↑, 1, hepatoP↑, 1, neuroP↑, 2, RenoP↑, 1,
Total Targets: 31

Scientific Paper Hit Count for: Hif1a, HIF1α/HIF1a

14 Baicalein
1 Radiotherapy/Radiation
1 tamoxifen
1 Baicalin
1 5-fluorouracil

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:38  Target#:143  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

Baicalein / Hif1a Cancer Research Results

Mechanistic table

Pathway results for Effect on Cancer / Diseased Cells:

Redox & Oxidative Stress ⓘ

Mitochondria & Bioenergetics ⓘ

Core Metabolism/Glycolysis ⓘ

Cell Death ⓘ

Kinase & Signal Transduction ⓘ

Protein Folding & ER Stress ⓘ

Autophagy & Lysosomes ⓘ

DNA Damage & Repair ⓘ

Cell Cycle & Senescence ⓘ

Proliferation, Differentiation & Cell State ⓘ

Migration ⓘ

Angiogenesis & Vasculature ⓘ

Barriers & Transport ⓘ

Immune & Inflammatory Signaling ⓘ

Drug Metabolism & Resistance ⓘ

Clinical Biomarkers ⓘ

Functional Outcomes ⓘ

Pathway results for Effect on Normal Cells:

Redox & Oxidative Stress ⓘ

Core Metabolism/Glycolysis ⓘ

Cell Death ⓘ

Proliferation, Differentiation & Cell State ⓘ

Angiogenesis & Vasculature ⓘ

Immune & Inflammatory Signaling ⓘ

Clinical Biomarkers ⓘ

Functional Outcomes ⓘ

Home Page